What is cangrelor studying for acute ischemic stroke?

Cangrelor is being studied to see if adding it to mechanical thrombectomy and best medical management improves recovery in people with acute ischemic stroke. Researchers want to find out if this combination helps patients regain better function three months after their stroke. The study is sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

Who may be eligible for this acute ischemic stroke clinical trial?

Adults aged 18 to 80 years who have had a recent acute ischemic stroke caused by a blockage in the brain's large arteries may be eligible. Participants must have a moderate stroke severity and mild or no disability before the stroke. The study includes both men and women. Please review eligibility criteria for more details.

Is there any cost to participate in this acute ischemic stroke clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel or accommodation costs.

Actively Recruiting

Phase 3

Age: 18Years - 80Years

All Genders

ID04667078

REperfusion With P2Y12 Inhibitors in Addition to Mechanical Thrombectomy for Perfusion Imaging Selected Acute Stroke Patients REPERFUSE

Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2026-03-02

368

Participants Needed

Research Sites

26 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are investigating the effect of adding an intravenous P2Y12 inhibitor called cangrelor to mechanical thrombectomy MT and best medical management BMM in patients with acute ischemic stroke. This study focuses on adults who have a stroke caused by a large artery blockage in the brain and are eligible for MT within 24 hours of symptom onset based on brain imaging. The goal is to see if this combination treatment improves functional recovery at 3 months compared to MT and BMM alone. Participants will be randomly assigned to one of two groups. One group will receive cangrelor through an IV bolus followed by an infusion during the MT procedure, which lasts up to 4 hours, and then transition to oral antiplatelet therapy after stopping the infusion. The other group will receive best medical management alongside MT, including authorized antithrombotic drugs like alteplase if guidelines are met. The choice of MT technique is left to the treating physician. During the study, participants will undergo assessments to evaluate their functional status at 3 months after treatment. Researchers will monitor the patients recovery and safety, focusing on the ability to perform daily activities. The study includes careful imaging and clinical evaluations to ensure eligibility and measure outcomes. Total participation time includes the treatment period and follow-up at 3 months to assess results.

CONDITIONS

Brief Title

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

Who Can Participate

Age: 18Years - 80Years

All Genders

Eligibility Criteria

You may qualify if you...

Age 18 or older
Confirmed blockage in the brain's anterior circulation large arteries (intracranial ICA and/or MCA) by CTA or MRA
Stroke symptoms started less than 24 hours before imaging
Eligible for mechanical thrombectomy and meeting brain imaging criteria including infarct volume and perfusion ratios or clinical mismatch
Pre-stroke modified Rankin Scale score of 2 or less
National Institutes of Health Stroke Scale score of 6 or higher

You will not qualify if you...

Contraindication to mechanical thrombectomy
Age over 80 with more than 10 microbleeds on MRI before treatment
Pre-existing significant disability with modified Rankin Scale score of 3 or higher
Known tandem ICA-MCA occlusions needing stenting
ASPECT score less than 6 on CT or MRI
Known allergy to cangrelor or its ingredients (mannitol, sorbitol)
History of previous brain bleeding
Active bleeding or recent trauma
Recent surgery with high bleeding risk
High INR above 1.7 if taking vitamin K antagonists
Recent use of certain anticoagulants with specific blood levels
Platelet count below 100,000 per mm3
Women of childbearing age without a pregnancy test or with a positive test
Under legal protection
Not covered by a national insurance scheme
Patient or trusted person opposes participation
Participation in another interfering acute ischemic stroke study

Research Team

Mikael Pr MAZIGHI, Pr

Amélie YAVCHITZ, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here